----- Forwarded message -----

From: Santhigiri Scientific and Industrial Research Institute < ssiri.srf@santhigiriashram.org>

Date: Mon, Mar 27, 2023 at 5:27 PM

Subject: Confirmation regarding the proposed In-Vivo Study

To: <pri>principal@nirmalacp.org>

Dear Sir,

We received your proposal for an in-vivo study of Snehakanthi Capsule, an anti-diabetic formulation of Santhigiri Ayurveda & Siddha Vaidyasala, in response to their request. The matter has been reviewed, and we hereby officially extend our consent. Our research laboratory, Navajyothi Sree Karunakara Guru Research Centre for Ayurveda & Siddha, will assist with monetary and other study-related activities. Once sent, we will intimate you of the payment details for the first instalment. Expecting your patronage at all times.

With Prayers

Dr B Rajkumar Medical Superintendent (Ayurveda) Santhigiri Healthcare & Research Organization Additional Charge Santhigiri Scientific & Industrial Research Institute

← Reply

→ Forward

<



Principal Pharmacy <principal@nirmalacp.org>

Transaction details of payment made

1 message

Santhigiri Scientific and Industrial Research Institute <ssiri.srf@santhigiriashram.org>

Sun, May 14, 2023 at 11:24 AM

To: Principal Pharmacy <principal@nirmalacp.org>

Dear Sir.

Please refer to the attached PDF for the specifics of our first payment of twenty thousand two hundred ninety-two rupees (20,292) on April 17, 2023. Once your bank has confirmed that the payment has been credited to your account, kindly send us an acknowledgment.

With Prayers,

Dr Brahmadathan U Additional Medical Officer (Production - Siddha) Santhigiri Ayurveda Siddha Vaidyasala Additional Charge SSIRI

With Prayers

Dr B Rajkumar Medical Superintendent (Ayurveda) Santhigiri Healthcare & Research Organization Additional Charge Santhigiri Scientific & Industrial Research Institute

Santhigiri Healthcare and Research Organization

Santhigiri Ashram, Santhigiri P.O Thiruvananthapuram-685 589. Kerala, India. www.Santhigiriashram.

Phone.0471 2719342, 0860685 3000, 4000, 5000

Mail Disclaimer

Any view or opinion presented in this email is solely of the author and does not necessarily represent that of Santhigiri Ashram. Employees of the Ashram are expressly required not to make defamatory statements and not to infringe or authorize any infringement of copyright or any other legal right by email communications. The Ashram will not accept any liability in respect of such communication, and the employee responsible will be personally liable for any damages or other liabilities arising.

Warning: Although the Ashram has taken reasonable precautions to ensure no viruses are present in this email, it cannot accept responsibility for any loss or damage arising from the use of this email or attachments.

Transaction details 20292.pdf 383K

P. Bedmento Nirmala College of Pharmacy Muvattupuzha, Ernakulam (Dist.) Kerala - 686 661



View Transaction Details

NAVAJ(INR)-06850200000506

Value Date: 17/04/2023

Entry Date: 17/04/2023

Amount Type: Dr.

Amount: INR 20,292.00

Sending Bank Reference: \$64632223

Supplementary Details:

Reference for Account

Additional Details (Tag 86):

Owner:

Transaction Remarks:

NEFT-BARBU23107135873-RESEARCH AND DEVELOPMENT

Transaction Time: 17/04/2023 12:08:16 PM

IST

Branch Name: KOTTAYAM, KERALA

Account Balance(INR): 14,486.90

Account Type: Current

ANIMAL PHARMACOLOGICAL EVALUATION OF SNEHAKANTHI CAPSULE FOR ITS ANTIDIABETIC ACTIVITY

ABOUT THE MEDICINE (Details provided by the manufacturer)

Primary evaluation of the composition of the study medicine based on literature and past research evidence, shows that the components are individually stated or proven to have antidiabetic potential. The proposed animal pharmacological evaluation of the medicine can evaluate its antidiabetic and antioxidant potentials and can through light on the pharmacokinetics of the medicine.

PERTINENCE OF THE STUDY

In order to apply for a license for a new drug for sale in the country, item (2) of Rule 122-B of Drugs & Cosmetics Rules 1945, mandates the submission of clinical trial reports. While applying for a human clinical trial for a New Drug / Investigational New Drug as per Rule 122-DA, the information and data as required under Schedule Y have to be submitted and the Schedule Y guidelines mandate the submission of animal pharmacology data. But, for a license with respect to a Patent or Proprietary Ayurveda, Siddha or Unani Drug (under Rule 158-B, item II (B)) only pilot study data is required.

Although the statutory requirements are like this, an animal pharmacological evaluation of the proposed drug is pertinent in the following aspects:

- For standardizing the formulation;
- For standardizing the dosage;
- For understanding the potential contraindications;
- For understanding the pharmacokinetics of the medicine;
- For generating evidence on the safety and effectiveness of the medicine;
- For better placement of a novel antidiabetic herbal formulation in the market,
 while there is a lot of such formulations already running in the market.

STUDY CENTRE DETAILS

Nirmala College of Pharmacy, Muvattupuzha, Ernakulam, Kerala, 686661. CPCSEA Registration No: 1411/PO/Re/S/11/CPCSEA

Date of Registration: 27 April 2018

The college has a registered Institutional Animal Ethics Committee (IAEC) and Animal House maintained in accordance with the applicable rules and regulations.

About the College(Citation: www.nirmalacp.org)

Nirmala College of Pharmacy (NCP) is a Christian minority institution established in 2004 as a memorial of the diocesan golden jubilee. It is managed by the Catholic Diocese of Kothamangalam under the Nirmala College Society (Reg. No. ER.928/2001). At present, the college is affiliated with the Kerala University of Health Sciences, Thrissur. This college is approved by the Government of Kerala and the Pharmacy Council of India (PCI), New Delhi. The college aims at the formation of students with academic excellence coupled with the integrity of character. It provides excellent infrastructural facilities with all modern amenities, and a dedicated and experienced faculty with a vision to develop the institution into a full-fledged pharma research centre.

Certificate / Accreditation / Recognition	Authority
Certificate of International Accreditation	International Accreditation Organization
ISO 9001:2015 (No: UCQ-2104487)	Universal Certification Ltd. American Accreditation Board
NBA Accreditation of UG Pharmacy Course	National Board of Accreditation

STUDY INVESTIGATOR(S)

Name	Designation	Role	Experience in Lab Animal Experimentation
Ms. Elayath Parvathy Murali	Assistant Professor, Parvathy Murali Dept. of Pharmacology		5.4 Years
Dr. Badmanaban R. Professor, Dept. of Pharmacognosy		Co-guide	19 Years

EVALUATION STRATEGY, OBJECTIVES AND TIME PERIOD

EVALUATION	OBJECTIVE	TIME PERIOD (IN DAYS)	
Acute Toxicity	To assess the general toxic effects of	14 days	
Evaluation	test drug based on OECD guideline 223	Acclimatisation: 7 Days Study Period: 7 Days	
Invivo Evaluation of Antidiabetic Activity	To evaluate the dose-dependent (low & high) anti-diabetic potential of the drug compared with a standard antidiabetic drug (Glibenclamide - 10 mg per Kg).	39 days Acclimatisation: 14 Days Study Period: 25 Days	
Exvivo Histopathologica I studies on the pancreas and kidney	To assess the mode of action and effect of the medicine, on the internal organs where its action is anticipated.	20 Days	
Exvivo Antioxidant studies	Antioxidant the drug		
A - Total Study	Period (Inclusive of Acclimatisation Period)	120 Days	
Report Submission		30 Days	
Publication	Publication		
	B - Subtotal		
То	otal Project Period (A+B)	330 Days	

STATISTICAL TEST ANOVA Fixed effects, Omnibus, one-way

DRUGS REQUIRED FOR STUDY

Drug	Manufacturer	Qty Req.	Action	Purpose
Streptozotocin	Sisco Research Pvt. Ltd.or other vendor	500 mg	Toxic to Pancreatic β-cells that secretes Insulin	To induce diabetes mellitus in study organism

Drug	Manufacturer	Qty Req.	Action	Purpose
Glibenclamide	TCI Chemicals Ltd./ or other vendor	5 g	Increases Pancreatic β-cell secretion	Standard Antidiabetic Drug for comparative evaluation
Snehakanthi Capsule	Santhigiri Ayurveda & Siddha Vaidyasala	100 Capsul es		Study Drug

ANIMAL REQUIREMENT FOR THE STUDY

Animal	Count (In Nos)	Gender	Evaluation	Guidelines
Wistar Albino Rat	9	Female	Acute Toxicity Study	OECD Guideline 423
Wistar Albino Rat	40	Male / Female	Antidiabetic study	

Disease free animals will be purchased from College of Veterinary and Animal Sciences, Mannuthy, Thrissur.

MILESTONES AND STATUS

Milestone	Period (In Days)	Status
IAEC Approval		Done
CPCSEA Approval		Done
Purchase / obtaining animals and drugs	30 Days	To Do
Study Period	120 Days	To Do
Consolidation and Report Submission	30 Days	To Do
Publication	180 Days	To Do

MEASURABLE OUTCOME(S)

Published animal pharmacological study of Snehakanthi Capsule, on its safety and effectiveness, as an antidiabetic herbal formulation.

CONSOLIDATED BUDGET ESTIMATE

SN	Phase	Exp of A	Exp of B
1	Phase 1	₹40,000	₹20,292
2	Phase 2		₹21,500
3	Phase 3		₹10,000
4	Phase 4		₹5,000
	Total	₹40,000	₹56,792
	Grand Total		₹96,792

A: Nirmala College of Pharmacy, B: Santhigiri Ayurveda & Siddha Vaidyasala

Detailed budget Estimate with Break-up of Expenditure - Annexure 1.

FUND RELEASE / UTILIZATION STRATEGY

At the end of each phase, the College will intimate the same with the details of fund utilisation, substantiated with copies of the bills and a *Utilisation Certificate* in the format given in Annexure 2. At the end of the project, a *Completion Certificate* will also be issued on the letterhead of the institution, a template of which is enclosed as Annexure 3.

Payment Terms

The amount estimated for the activities of each phase has to be credited to the account details mentioned hereunder prior to the beginning of the phase. The UTR Number of the transaction has to be shared to our mail after each payment:

Bank - Branch : Catholic Syrian Bank - Muvattupuzha

Account Name : Research and Development Cell Nirmala Pharmacy - A Unit of

Nirmala College Society

Account Number : 006800838079190001

IFSC Code : CSBK0000068

ANNEXURE 1

ANIMAL PHARMACOLOGICAL EVALUATION OF SNEHAKANTHI CAPSULE FOR ITS ANTIDIABETIC ACTIVITY

BUDGET ESTIMATE

SN	ITEM	RATE	QTY	AMOUNT	EXP OF A	EXP OF B
Phas	Phase 1					
1	IAEC Sitting Charges	-	-	₹35,000	₹35,000	-
2	Wistar Albino Rats	₹150 per Rat	49 Nos	₹7,350	-	₹7,350
3	Animal Transportation	-	-	₹5,000	₹5,000	-
4	Streptozotocin	₹18,980 per g	0.5 g	₹9,490	-	₹9,490
5	Glibenclamide	₹690.50 per g	5 g	₹3,452	-	₹3,452
	Subtotal (A)			₹60,292	₹40,000	₹20,292
Phas	e 2					
8	Histopathological Studies (Pancrease 6, Kidney 6)	₹650 per sample	10 samples	₹6,500	-	₹6,500
9	Oxidative Biomarkers	₹1,000 per sample	15 samples	₹15,000	-	₹15,000
	Subtotal (B)			₹21,500		₹21,500
Phas	e 3					
10	Report Preparation and Submission	-	-	₹2,000	-	₹2,000
11	Consultancy Charges	-	-	₹8,000	-	₹8,000

SN	ITEM	RATE	QTY	AMOUNT	EXP OF A	EXP OF B
	Subtotal (C)			₹10,000		₹10,000
Phas	se 4					
12	Publication Charges	-	-	₹5,000		₹5,000
	Subtotal (D)			₹5,000		₹5,000
	GRAND TOTAL (A+B+C+D)			₹96,792	₹40,000	₹56,792

A: Nirmala College of Pharmacy, B: Santhigiri Ayurveda & Siddha Vaidyasala

Total budget estimate is ₹96,792 (Rupees Ninety-Six Thousand Seven Hundred Ninety-Two Only).

CODE	PARTY	BEARING EXPENSE		
		VALUE	%	
Α	Nirmala College of Pharmacy	₹40,000	41.32%	
В	Santhigiri Ayurveda & Siddha Vaidyasala	₹56,792	58.67%	
	TOTAL	₹96,792		

Powaltry

Mrs.Elayath Parvathy Murali Technical expert/ Guide

Contact no: 9847366397

Email: el.parvathy@gmail.com

Dr.Badmanaban.R
Authorized person /Co-guide

Dr. BADMANABAN. R
PRINCIPAL
Nirmala College of Pharmacy
Muvattupuzha, Ernakulam (Dist.)
Kerala - 686 661

Date: 24/01/2023